Shamik Chakraborty, MD, senior neurosurgery resident from the Brain Tumor Biotech Center at the Feinstein Institute for Medical Research, was named as the first place winner of the “Resident Research Award” from the New York Society of Neurosurgery.
At the Society’s annual meeting on Aug 3rd, Dr. Chakraborty was recognized for his presentation “Overcoming the Blood/Brain Barrier for the Treatment of Malignant Brain Tumors,” where he discussed research he performed over the past year, under the mentorship of John Boockvar, MD and Marc Symons, PhD., of the Brain Tumor Biotech Center, part of Northwell Health.
“Malignant brain tumors are difficult to treat because they are often hidden behind the blood/brain barrier, the natural part of the brain’s protection, which safeguards from harmful toxins including many types of chemotherapy,” said Dr. Chakraborty. “Therefore, when treating malignant brain tumors we have to use high doses of chemotherapy which often doesn’t adequately treat the tumors and may produce negative side effects on the body.”
Dr. Chakraborty explains that in his research, he used drug delivery agents called paramagnetic nanoparticles, which were directed using powerful magnets to only the area of brain tumors implanted in mice. Dr. Chakraborty’s research showed that the blood/brain barrier in the area around the tumor was disrupted after using the paramagnetic nanoparticles, sparing the rest of the brain.
This groundbreaking research showed that paramagnetic nanoparticles coupled with anti-tumor drugs could potentially target and penetrate just in the area of and surrounding the brain tumor. One of the main advantages of this potential treatment modality is that it reduces the amount of chemotherapy needed, while at the same time, increases the concentration at the tumor site, lessening the dose to the rest of the body.
For more information about the Brain Tumor Biotech Center at the Feinstein Institute for Medical Research, click here.
About the Feinstein Institute
The Feinstein Institute for Medical Research is the research arm of Northwell Health, the largest healthcare provider in New York. Home to 50 research laboratories and to clinical research throughout dozens of hospitals and outpatient facilities, the 2,000 researchers and staff of the Feinstein are making breakthroughs in molecular medicine, genetics, oncology, brain research, mental health, autoimmunity, and bioelectronic medicine – a new field of science that has the potential to revolutionize medicine. For more information about how we empower imagination and pioneer discovery, visit FeinsteinInstitute.org.